Kobayashi Pharmaceutical Co Ltd
XMUN:KOY

Watchlist Manager
Kobayashi Pharmaceutical Co Ltd Logo
Kobayashi Pharmaceutical Co Ltd
XMUN:KOY
Watchlist
Price: 30.4 EUR 0.66% Market Closed
Market Cap: €4B

Wall St Price Targets

KOY Price Targets Summary
Kobayashi Pharmaceutical Co Ltd

Wall Street analysts forecast KOY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KOY is 31.09 EUR with a low forecast of 22.12 EUR and a high forecast of 39 EUR.

Lowest Forecast
Price Target
22.12 EUR
27% Downside
Average Forecast
Price Target
31.09 EUR
2% Upside
Highest Forecast
Price Target
39 EUR
28% Upside
Kobayashi Pharmaceutical Co Ltd Competitors:
Price Targets

Revenue
Forecast

1% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
1% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 8 years, the compound annual growth rate for Revenue has been 1%. The projected CAGR for the next 3 years is 4%.

Gross Profit
Forecast

-1% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
-1% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 8 years, the compound annual growth rate for Gross Profit has been -1%. The projected CAGR for the next 3 years is 5%.

Operating Income
Forecast

-5% / Year
Past Growth
31% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
-5% / Year
Past Growth
31% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 8 years, the compound annual growth rate for Operating Income has been -5%. The projected CAGR for the next 2 years is 31%.

Pre-Tax Income
Forecast

-20% / Year
Past Growth
86% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
-20% / Year
Past Growth
86% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Over the last 8 years, the compound annual growth rate for Pre-Tax Income has been -20%. The projected CAGR for the next 3 years is 86%.

Net Income
Forecast

-17% / Year
Past Growth
72% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
-17% / Year
Past Growth
72% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 8 years, the compound annual growth rate for Net Income has been -17%. The projected CAGR for the next 3 years is 72%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is KOY's stock price target?
Price Target
31.09 EUR

According to Wall Street analysts, the average 1-year price target for KOY is 31.09 EUR with a low forecast of 22.12 EUR and a high forecast of 39 EUR.

What is the Revenue forecast for Kobayashi Pharmaceutical Co Ltd?
Projected CAGR
4%

Over the last 8 years, the compound annual growth rate for Revenue has been 1%. The projected CAGR for the next 3 years is 4%.

What is the Gross Profit forecast for Kobayashi Pharmaceutical Co Ltd?
Projected CAGR
5%

Over the last 8 years, the compound annual growth rate for Gross Profit has been -1%. The projected CAGR for the next 3 years is 5%.

What is the Operating Income forecast for Kobayashi Pharmaceutical Co Ltd?
Projected CAGR
31%

Over the last 8 years, the compound annual growth rate for Operating Income has been -5%. The projected CAGR for the next 2 years is 31%.

What is the Pre-Tax Income forecast for Kobayashi Pharmaceutical Co Ltd?
Projected CAGR
86%

Over the last 8 years, the compound annual growth rate for Pre-Tax Income has been -20%. The projected CAGR for the next 3 years is 86%.

What is the Net Income forecast for Kobayashi Pharmaceutical Co Ltd?
Projected CAGR
72%

Over the last 8 years, the compound annual growth rate for Net Income has been -17%. The projected CAGR for the next 3 years is 72%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett